NEU 3.32% $20.52 neuren pharmaceuticals limited

Neuren Media and Analyst Coverage, page-1073

  1. 6,044 Posts.
    lightbulb Created with Sketch. 1589
    I am also on board with Tony. Absolutely no disrespect for those doing valuations, but IMO the real valuation is our SP, irrespective of manipulation or no manipulation.

    The current SP and the journey to get there strongly suggests to me that, pending another successful P2 (Angelman's) and forecast Daybue sales, we will be in the running for a circa $50 T/O offer.

    I may be wrong, but if that eventuates, I will also predict that at that figure it would be accepted by management and the major holders.

    IMO, fair enough. It has been a long, slow risky journey to get to this point and all journey's must finish at some point. Sure, there may be tremendous scope for much more, but that scope would still entail plenty of risk. There comes a time when a bird in the hand is worth accepting, and at $50 that would do it for me.

 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.